Adverse events should be reported.
Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated for symptomatic treatment of focal spasticity of:
- Upper limbs in adults
- Lower limbs in adults affecting the ankle joint
Please click here to see the full therapeutic indications.
Adult Spasticity
Tackling the capacity challenge in your clinics with Dysport®
12 minutes
Dr Michelle Kirkland discusses Dysport® time to retreatment in clinical trials and how moving to Dysport® may allow adult patients with focal spasticity to avoid unnecessary appointments and contribute to increasing clinic capacity.
DYS-UK-008739
A practical guide to implementing a flexible PIFU model
22 minutes
How the implementation of a Patient-Initiatied Follow-Up (PIFU) model may be a practical solution to capacity challenges and help achieve efficiency savings within BoNT-A services.
DYS-UK-008737
Making sense of the changing NHS and funding flows
12 minutes
Dr Judy Willits discusses how the NHS payment scheme has evolved and what the changes could mean for your botulinum toxin services.
DYS-UK-008730
Navigating the Switch between BoNT-As: The North Staffordshire Rehabilitation Centre Experience
10 minutes
Dr Clive Bezzina shares his personal experience switching between BoNT-As within his spasticity service, and the outcomes seen for both the patients and the service.
DYS-UK-008724
© IPSEN Ltd, 5th Floor The Point, 37 North Wharf Road, London, W2 1AF, United Kingdom. All rights reserved. September 2024 DYS-UK-008822
